Published in
Elsevier, Contemporary Clinical Trials, (90), p. 105892, 2020
DOI: 10.1016/j.cct.2019.105892
Links
Tools
A physician-initiated double-blind, randomised, placebo-controlled, phase 2 study evaluating the efficacy and safety of inhibition of NADPH oxidase with the first-in-class Nox-1/4 inhibitor, GKT137831, in adults with type 1 diabetes and persistently elevated urinary albumin excretion: Protocol and statistical considerations
Journal article published in 2020 by
Anne T. Reutens,
Karin Jandeleit-Dahm,
Merlin Thomas 
,
Agus Salim,
Alysha M. De Livera,
Leon A. Bach,
Peter G. Colman,
Timothy M. E. Davis,
Elif I. Ekinci ,
Greg Fulcher,
Peter Shane Hamblin ,
Mark A. Kotowicz,
Richard J. MacIsaac,
Claire Morbey,
David Simmons
and other authors.
,
Agus Salim,
Alysha M. De Livera,
Leon A. Bach,
Peter G. Colman,
Timothy M. E. Davis,
Elif I. Ekinci ,
Greg Fulcher,
Peter Shane Hamblin ,
Mark A. Kotowicz,
Richard J. MacIsaac,
Claire Morbey,
David Simmons
and other authors.
This paper was not found in any repository, but could be made available legally by the author.
Full text: Unavailable
Published version:
archiving forbidden
Data provided by 